Abstract
Sera from 71 patients with primary Sjögren's syndrome (PSS) and from 102 patients with systemic lupus erythematosus (SLE) were tested by immuno-dot blotting against HuD, Ri, Yo and amphiphysin recombinant proteins.
For Ri, Yo and amphiphysin antigens, no immunoreactivity was found in the 173 sera tested. One PSS patient with a clinical picture of subacute sensory neuronopathy had high titers of anti-Hu antibodies. An extensive search for an underlying tumor was initially negative but a small cell lung cancer was eventually discovered three years later.
Another patient with SLE and a clinical picture of demyelinating polyradiculoneuropathy had anti-Hu antibodies. Repeated search for an underlying tumor remains negative after five years follow-up in this young non-smoking patient. In addition, the neuropathy progressively improved and the anti-Hu antibodies titer slowly decreased from 1 : 8000 to 1 : 2000, making the diagnosis of paraneoplastic syndrome unlikely in this patient.
This study indicates that the detection of anti-Hu antibodies in patients with known symptomatic systemic autoimmune diseases such as PSS or SLE should induce the same work-up than the detection of these antibodies in the absence of other immune diseases, i.e. repeated search for occult cancer during several years. As illustrated by our first patient, this strategy may be fruitful. Nevertheless, the clinician should know that anti-Hu antibodies may exceptionally (0.6% in this series) occur in systemic autoimmune disorders with neurological complications, in the absence of an underlying neoplastic disease.
Similar content being viewed by others
References
Alexander EL, Provost TT, Stevens MB, Alexander GE: Neurologic complications of primary Sjögren's syndrome. Medicine (Baltimore) 61: 247–257, 1982
Huynh C, Ho SL, Fong KY, Cheung RT, Mok CC, Lau CS: Peripheral neuropathy in systemic lupus erythematosus. J Clin Neurophysiol 16: 164–168, 1999
Sillevis-Smitt P, Manley G, Moll JW, Dalmau J, Posner JB: Pitfalls in the diagnosis of autoantibodies associated with paraneoplastic neurologic disease. Neurology 46: 1739–1741, 1996
Manley GT, Smitt PS, Dalmau J, Posner JB: Hu antigens: reactivity with Hu antibodies, tumor expression, and major immunogenic sites. Ann Neurol 38: 102–110, 1995
Vitali C, Bombardieri S, Moutsopoulos HM, Coll J, Gerli R, Hatron PY, Kater L, Konttinen YT, Manthorpe R, Meyer O, Mosca M, Ostuni P, Pellerito RA, Pennec Y, Porter SR, Richards A, Sauvezie B, Schiodt M, Sciuto M, Shoenfeld Y, Skopouli FN, Smolen JS, Soromenho F, Tishler M, Wattiaux MJ: Assessment of the European classification criteria for Sjögren's syndrome in a series of clinically defined cases: results of a prospective study. Ann Rheum Dis 55: 116–121, 1996
Hochberg MC: Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725, 1997
Carpentier AF, Chassande B, Amoura Z, Benyahia B, Piette JC, Delattre JY: Systemic Lupus Erythematosus with anti-Hu antibodies and regressive polyradiculoneuropathy. Neurology 57: 558–559, 2001
Darnell RB, DeAngelis LM: Regression of small-cell lung carcinoma in patients with paraneoplastic neuronal antibodies. Lancet 341: 21–22, 1993
Lucchinetti CF, Kimmel DW, Lennon VA: Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies. Neurology 50: 652–657, 1998
Byrne T, Mason WP, Posner JB, Dalmau J: Spontaneous neurological improvement in anti-Hu associated encephalomyelitis. J Neurol Neurosurg Psychiatr 62: 276–278, 1997
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Benyahia, B., Amoura, Z., Rousseau, A. et al. Paraneoplastic antineuronal antibodies in patients with systemic autoimmune diseases. J Neurooncol 62, 349–351 (2003). https://doi.org/10.1023/A:1023396020559
Issue Date:
DOI: https://doi.org/10.1023/A:1023396020559